Literature DB >> 23144180

Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment.

Jacinta L Johnson1, Mark R Hutchinson, Desmond B Williams, Paul Rolan.   

Abstract

INTRODUCTION: Patients with chronic headache who consume large amounts of analgesics are often encountered in clinical practice. Excessive intake of analgesics is now considered to be a cause, rather than simply a consequence, of frequent headaches, and as such the diagnosis "medication-overuse headache" (MOH) has been formulated. Despite the prevalence and clinical impact of MOH, the pathophysiology behind this disorder remains unclear and specific mechanism-based treatment options are lacking. DISCUSSION: Although most acute headache treatments have been alleged to cause MOH, here we conclude from the literature that opioids are a particularly problematic drug class consistently associated with worsening headache. MOH may not be a single entity, as each class of drug implicated may cause MOH via a different mechanism. Recent evidence indicates that chronic opioid administration may exacerbate pain in the long term by activating toll-like receptor-4 on glial cells, resulting in a pro-inflammatory state that manifests clinically as increased pain. Thus, from the available evidence it seems opioid-overuse headache is a phenomenon similar to opioid-induced hyperalgesia, which derives from a cumulative interaction between central sensitisation, due to repeated activation of nociceptive pathways by recurrent headaches, and pain facilitation due to glial activation.
CONCLUSION: Treatment strategies directed at inhibiting glial activation may be of benefit alongside medication withdrawal in the management of MOH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23144180     DOI: 10.1177/0333102412467512

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  16 in total

Review 1.  Medication overuse headache.

Authors:  Valerie Cheung; Farnaz Amoozegar; Esma Dilli
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

Review 2.  Opioid-induced central immune signaling: implications for opioid analgesia.

Authors:  Peter M Grace; Steven F Maier; Linda R Watkins
Journal:  Headache       Date:  2015-03-31       Impact factor: 5.887

Review 3.  Medication-overuse headache: a perspective review.

Authors:  Maria Lurenda Westergaard; Signe Bruun Munksgaard; Lars Bendtsen; Rigmor Højland Jensen
Journal:  Ther Adv Drug Saf       Date:  2016-06-30

Review 4.  Medication Overuse Headache: The Reason of Headache That Common and Preventable.

Authors:  Elif Kocasoy Orhan; Betül Baykan
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

Review 5.  Chronic Daily Headache: Mechanisms and Principles of Management.

Authors:  Amy W Voigt; Harry J Gould
Journal:  Curr Pain Headache Rep       Date:  2016-02

6.  Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse.

Authors:  Maria Lurenda Westergaard; Ebba Holme Hansen; Charlotte Glümer; Rigmor Højland Jensen
Journal:  Eur J Clin Pharmacol       Date:  2015-05-14       Impact factor: 2.953

7.  Opioids can be useful in the treatment of headache.

Authors:  Cinzia Finocchi; Erica Viani
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

Review 8.  Neuroimaging Findings in Patients with Medication Overuse Headache.

Authors:  Tzu-Hsien Lai; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2018-01-16

Review 9.  The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update.

Authors:  Christina Sun-Edelstein; Alan M Rapoport; Wanakorn Rattanawong; Anan Srikiatkhachorn
Journal:  CNS Drugs       Date:  2021-05-17       Impact factor: 5.749

10.  TLR 2 and 4 responsiveness from isolated peripheral blood mononuclear cells from rats and humans as potential chronic pain biomarkers.

Authors:  Yuen H Kwok; Jonathan Tuke; Lauren L Nicotra; Peter M Grace; Paul E Rolan; Mark R Hutchinson
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.